#Africa

Treating within hours—rather than the recommended weeks—of birth also prompts an improved immune response against the virus.

New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.

Genetic sequencing indicated that three samples from 1983 to 2001 were all part of a newly established subtype L of group M of the virus.

The rollout of antiretroviral treatment in this hard-hit region has apparently not lowered this group’s risk of acquiring HIV.

In theory, starting antiretrovirals quiets the immune system, leading more immune cells to become part of the inactive reservoir.

That is according to a meta-analysis including nearly 500 people.

Researchers gave the vaccine, previously studied in Thailand, to participants in South Africa.

A recent study allayed concerns that certain forms of birth control were associated with an increased risk of acquiring the virus.

Events are scheduled throughout September to raise awareness about hep B and HIV in these communities.

Listen up: This powerhouse from Cameroon offers everyone an intentional conversation about power, privilege and accountability.

It likely aided the human species’s expansion but was eventually outmatched by an evolving virus.

The ordained Baptist reverend talks about the intersections of religion, HIV/AIDS and the South.

A look at September issues from the POZ archives

Formerly at Oxfam, Winnie Byanyima is the executive director of UNAIDS. She says fighting the epidemic is “very personal.”

The PopART study is one of three that have recently reported findings of such programs in sub-Saharan Africa.

The vaccine in the APPROACH study, which led to the Imbokodo and forthcoming Mosaico trails, prompted a robust immune response.